CA2160878A1 - Encapsulation d'acides nucleiques a l'aide de conjugues qui ciblent et facilitent l'absorption cellulaire et l'expression genique - Google Patents

Encapsulation d'acides nucleiques a l'aide de conjugues qui ciblent et facilitent l'absorption cellulaire et l'expression genique

Info

Publication number
CA2160878A1
CA2160878A1 CA002160878A CA2160878A CA2160878A1 CA 2160878 A1 CA2160878 A1 CA 2160878A1 CA 002160878 A CA002160878 A CA 002160878A CA 2160878 A CA2160878 A CA 2160878A CA 2160878 A1 CA2160878 A1 CA 2160878A1
Authority
CA
Canada
Prior art keywords
nucleic acid
acid
dna
poly
microparticle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002160878A
Other languages
English (en)
Inventor
Sandra Gertrude Mcelligott
Michael David Amos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MEDISORB TECHNOLOGIES INTERNATIONAL LP
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2160878A1 publication Critical patent/CA2160878A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Ceramic Engineering (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA002160878A 1993-04-19 1994-04-19 Encapsulation d'acides nucleiques a l'aide de conjugues qui ciblent et facilitent l'absorption cellulaire et l'expression genique Abandoned CA2160878A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4753693A 1993-04-19 1993-04-19
US08/047,536 1993-04-19

Publications (1)

Publication Number Publication Date
CA2160878A1 true CA2160878A1 (fr) 1994-10-27

Family

ID=21949539

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002160878A Abandoned CA2160878A1 (fr) 1993-04-19 1994-04-19 Encapsulation d'acides nucleiques a l'aide de conjugues qui ciblent et facilitent l'absorption cellulaire et l'expression genique

Country Status (6)

Country Link
EP (1) EP0696200A4 (fr)
JP (1) JPH08510639A (fr)
AU (1) AU6707194A (fr)
CA (1) CA2160878A1 (fr)
NZ (1) NZ265818A (fr)
WO (1) WO1994023738A1 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0615745B1 (fr) 1993-02-19 1997-05-02 Howard Green Compositions contenant des protéines à partir de corneocytes
US6348449B1 (en) * 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
WO1995024929A2 (fr) * 1994-03-15 1995-09-21 Brown University Research Foundation Systeme de liberation de genes polymeres
AUPM747694A0 (en) * 1994-08-16 1994-09-08 Commonwealth Scientific And Industrial Research Organisation Delivery of nucleic acids and peptides
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
JPH11510142A (ja) 1995-07-21 1999-09-07 ブラウン・ユニバーシティ・リサーチ・ファンデーション 核酸負荷ポリマー微粒子を使用した遺伝子治療法
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
GB9709900D0 (en) * 1997-05-15 1997-07-09 Microbiological Res Authority Microencapsulated DNA for vaccination and gene therapy
JP2000500744A (ja) * 1995-11-09 2000-01-25 マイクロバイオロジカル リサーチ オーソリティー ワクチン接種および遺伝子治療のためのマイクロカプセル化ｄｎａ
US20020165183A1 (en) * 1999-11-29 2002-11-07 Hans Herweijer Methods for genetic immunization
GB9619002D0 (en) * 1996-09-11 1996-10-23 Oxford Biosciences Ltd Particle delivery
US6893664B1 (en) * 1996-06-17 2005-05-17 Powderject Research Limited Particle delivery techniques
US6228624B1 (en) 1996-08-02 2001-05-08 Immunivest Corporation Method to select and transfect cell subpopulations
EP0934082B1 (fr) * 1996-10-23 2002-07-17 SKW Trostberg Aktiengesellschaft Procede de production de conjugues biologiquement actifs d'acides nucleiques et de nanoparticules polymeres
DE69837602T2 (de) * 1997-01-22 2008-01-17 MGI Pharma Biologics, Inc., Cambridge Mikropartikel zur verabreichung von nukleinsaeuren
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
EP2258846A3 (fr) 1997-07-07 2012-03-21 Medical Research Council Procédé d'amélioration de la concentration d'une molécule d'acide nucléique
IT1293088B1 (it) * 1997-07-10 1999-02-11 Isi Ist Sierovaccinogeno Ital Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6475994B2 (en) * 1998-01-07 2002-11-05 Donald A. Tomalia Method and articles for transfection of genetic material
JP3981525B2 (ja) 1998-01-20 2007-09-26 ハワード・グリーン 組織への物質のトランスグルタミナーゼ連結
AU2674299A (en) * 1998-02-11 1999-08-30 Maxygen, Inc. Targeting of genetic vaccine vectors
US6328967B1 (en) 1998-03-12 2001-12-11 Allergenics, Inc. Delivery system to modulate immune response
US6395253B2 (en) * 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
WO1999058656A2 (fr) * 1998-05-13 1999-11-18 The Regents Of The University Of Michigan Liberation prolongee d'adn depuis des matrices structurales
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
WO1999065531A1 (fr) * 1998-06-18 1999-12-23 Johns Hopkins University School Of Medicine Methodes et reactifs d'administration intramusculaire d'acides nucleiques
US6818626B1 (en) * 1998-07-17 2004-11-16 Mirus Corporation Chelating systems for use in the delivery of compounds to cells
US6916490B1 (en) 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
ES2243082T3 (es) 1998-10-01 2005-11-16 Powderject Research Limited Microparticulas con revestimiento aplicado por pulverizacion utilizadaen una jeringa sin aguja.
CA2276066A1 (fr) * 1999-03-11 2000-09-11 Zycos Inc. Microparticules pour diffusion d'un acide nucleique
US6767928B1 (en) 1999-03-19 2004-07-27 The Regents Of The University Of Michigan Mineralization and biological modification of biomaterial surfaces
CA2370063C (fr) 1999-03-19 2012-10-02 The Regents Of The University Of Michigan Mineralisation et developpement cellulaire superficiels sur des biomateriaux
WO2003045304A2 (fr) 2001-09-26 2003-06-05 Mayo Foundation For Medical Education And Research Vaccins mutables
GB0127564D0 (en) 2001-11-16 2002-01-09 Medical Res Council Emulsion compositions
EP1467711B1 (fr) * 2002-01-25 2007-03-21 Glaxo Group Limited Formes posologiques d'adn
GB0201736D0 (en) * 2002-01-25 2002-03-13 Glaxo Group Ltd DNA dosage forms
US20040048260A1 (en) * 2002-09-10 2004-03-11 Fu-Hsiung Chang Transfection of nucleic acid
JP4473878B2 (ja) 2003-01-29 2010-06-02 ４５４ コーポレーション 核酸を増幅および配列決定する方法
US20100022414A1 (en) 2008-07-18 2010-01-28 Raindance Technologies, Inc. Droplet Libraries
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
EP1641809B2 (fr) 2003-07-05 2018-10-03 The Johns Hopkins University Procédé et compositions de détection et d'énumeration de variations génétiques
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
EP3913375A1 (fr) 2006-01-11 2021-11-24 Bio-Rad Laboratories, Inc. Dispositifs microfluidiques et procédés d'utilisation dans la formation et contrôle de nanoréacteurs
GB0602637D0 (en) * 2006-02-09 2006-03-22 Glaxo Group Ltd Novel process
US20080003142A1 (en) 2006-05-11 2008-01-03 Link Darren R Microfluidic devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP2077912B1 (fr) 2006-08-07 2019-03-27 The President and Fellows of Harvard College Tensioactifs fluorocarbonés stabilisateurs d'émulsions
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008130623A1 (fr) 2007-04-19 2008-10-30 Brandeis University Manipulation de fluides, composants fluidiques et réactions dans des systèmes microfluidiques
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
EP3415235A1 (fr) 2009-03-23 2018-12-19 Raindance Technologies Inc. Manipulation de gouttelettes microfluidiques
EP2486409A1 (fr) 2009-10-09 2012-08-15 Universite De Strasbourg Nanomatériau marqué à base de silice à propriétés améliorées et ses utilisations
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
EP3392349A1 (fr) 2010-02-12 2018-10-24 Raindance Technologies, Inc. Analyse numérique d'analytes
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
EP2622103B2 (fr) 2010-09-30 2022-11-16 Bio-Rad Laboratories, Inc. Dosages sandwich dans des gouttelettes
EP3859011A1 (fr) 2011-02-11 2021-08-04 Bio-Rad Laboratories, Inc. Procédés permettant de former des gouttelettes mélangées
EP2675819B1 (fr) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Compositions et méthodes de marquage moléculaire
DE202012013668U1 (de) 2011-06-02 2019-04-18 Raindance Technologies, Inc. Enzymquantifizierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
US20220313616A1 (en) * 2021-03-30 2022-10-06 Celanese Eva Performance Polymers Llc Implantable Medical Device for the Delivery of Nucleic Acid-Encapsulated Particles

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248531A3 (fr) * 1986-05-02 1988-09-28 Southern Research Institute Acides nucléiques encapsulés
US4839111A (en) * 1987-02-02 1989-06-13 The University Of Tennessee Research Corporation Preparation of solid core liposomes
ATE104857T1 (de) * 1989-03-07 1994-05-15 Genentech Inc Kovalente konjugate von lipiden und oligonukleotiden.

Also Published As

Publication number Publication date
WO1994023738A1 (fr) 1994-10-27
EP0696200A1 (fr) 1996-02-14
JPH08510639A (ja) 1996-11-12
NZ265818A (en) 1997-09-22
EP0696200A4 (fr) 1998-04-15
AU6707194A (en) 1994-11-08

Similar Documents

Publication Publication Date Title
CA2160878A1 (fr) Encapsulation d'acides nucleiques a l'aide de conjugues qui ciblent et facilitent l'absorption cellulaire et l'expression genique
JPH08511418A (ja) 生分解性極微粒子からのアンチセンスオリゴデオキシリボヌクレオチドの徐放運搬による長期作用のある処置
Perales et al. An evaluation of receptor‐mediated gene transfer using synthetic DNA‐ligand complexes
US6090925A (en) Macromolecular microparticles and methods of production and use
US5981719A (en) Macromolecular microparticles and methods of production and use
US5952232A (en) Expandible microparticle intracellular delivery system
JP2000506865A (ja) インターフェロンをコードする遺伝子の標的を定めた送達
US20020012652A1 (en) Microspheres containing condensed polyanionic bioactive agents and methods for their production
US20120282343A1 (en) Compositions for oral gene therapy and methods of using same
JP2003535122A (ja) 生物活性物質のための送達システム
CA2190121A1 (fr) Systeme de liberation de genes polymeres
EA010056B1 (ru) Конструкции нуклеиновых кислот
US20090238883A1 (en) Liver-specific nanocapsules and methods of using
JP2009261411A (ja) 核酸を輸送するための微粒子
WO1997030731A2 (fr) Procede de preparation de complexes porteurs de polynucleotides pour administration a des cellules
JP2005511761A (ja) ナノ粒子送達ビヒクル
CN102666879A (zh) 模板化的纳米缀合物
JPH11510142A (ja) 核酸負荷ポリマー微粒子を使用した遺伝子治療法
KR20210133993A (ko) Rho-연관 상염색체-우성 망막색소변성증(adrp)을 치료하기 위한 crispr/rna-가이드 뉴클레아제-관련 방법 및 조성물
CN101184511A (zh) 包括由核酸分子和胶原组成的络合物精细颗粒的制剂
JP2005530695A (ja) 生理活性物質を細胞内に導入するエレクトロポレーション法
JP2002538198A (ja) キャリヤー媒介体及びターゲティング媒介体としての細菌ゴースト
JP2003061693A (ja) ウイルス様粒子、その製造方法およびその使用
JP2011088909A (ja) 核酸を送達するための微粒子
WO1998033478A2 (fr) Agents actifs a base d'arn et d'adn dans des nanoparticules

Legal Events

Date Code Title Description
FZDE Dead